(Note: Thank you for supporting businesses like the one presenting a sponsored message below and working with them through the links below which benefits Gateway

Tuesday, November 18, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on

On Monday, Novo Nordisk announced a discount on its popular drugs for diabetes and obesity, Ozempic and Wegovy, cutting prices for the lowest doses to

Plus, a profile on the latest startup challenging the dominance of DoorDash and Uber Eats, and a new GLP-1 menu tool

Key Points Weight loss pills could account for 25% of the market share over the long term. The GLP-1 market is expected to grow to

Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1

(MedPage Today) — Vanda Pharmaceuticals said its investigational neurokinin-1 receptor antagonist tradipitant reduced nausea and vomiting from semaglutide (Ozempic, Wegovy) in a randomized trial of

Thanks to the GLP-1 revolution, families across the country are negotiating new ways to connect over the holidays.

Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the “reward center” of the brain.

The surprising new use for GLP-1s: Alcohol and drug addiction  The Washington Post Taking Ozempic? Yale Researchers Say You’ll Handle Alcohol “Differently” and It Could Be

You might recognize this scene. Lunch was small, you feel full sooner than usual, and by late afternoon you are both a little hungry and

Originally developed for diabetes, GLP-1 drugs like Ozempic are showing remarkable potential in combating addiction. Emerging research suggests these medications can dampen cravings for alcohol

Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ahead of the

Healthcare, Vol. 13, Pages 2958: Evaluating Suicidal Risk in GLP-1RA Therapy: An Umbrella Review of Meta-Analytic Evidence Healthcare doi: 10.3390/healthcare13222958 Authors: Cristina Ștefănescu Elena Alexandra

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. As a reminder, STAT’s Isabella

Eli Lilly shares have room to keep rising as GLP-1 drugs spread reach The trillion-dollar club has become crowded with mostly tech names riding the

For Immediate Release Chicago, IL – November 18, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks

Eli Lilly Drug Shows New Potential in Curbing Food Cravings Eli Lilly and Company BATS:LLY DEXWireNews Eli Lilly’s GLP-1 weight-loss drug tirzepatide — sold as

Comparing one’s results with others’ is natural, but not necessarily helpful or fair. Medscape Medical News

No matter why a patient decides to stop using the popular drugs, be ready to help them transition and stay healthy. Medscape Medical News

There are cosmetic, psychological, and physical complications that can come from rapid weight loss. Medscape Medical News

Obesity is one of the fastest-growing global health crises, fueling diabetes, cardiovascular disease, and reduced life expectancy. Glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide,

What You Should Know: – GoodRx has unveiled two major initiatives to democratize access to GLP-1 medications: the launch of the GoodRx for Weight Loss

submitted by /u/Successful-Peach-764 [link] [comments]

President Trump wants to “make America slim again,” said Kara Kennedy in The Free Press. Standing beside drug execs in the Oval Office earlier this

Lala Kent admits that co-parenting 4-year-old daughter Ocean with ex Randall Emmett is not going well – Page Six Robbie Williams claims taking a GLP-1

A rare intracranial brain-recording study revealed that tirzepatide, a GLP-1 and GIP receptor agonist, temporarily silences craving-related neural activity in a key reward circuit of

Recent studies show the surging popularity of Ozempic, Wegovy and similar drugs for weight loss is driving employer health coverage costs higher.

Novo Nordisk said Monday it will immediately drop its cash-pay prices for megablockbusters Ozempic and Wegovy to $349 per month, more than six weeks before

About one in eight American adults are now taking GLP-1 drugs like Ozempic, Wegovy, Zepbound, and Mounjaro, a new survey shows—a sharp increase from just

Dr. David G. Davtyan of Weight Loss Surgery Los Angeles discusses how bariatric surgery continues to outperform GLP-1 medications in achieving long-term, sustainable weight loss.

By TOM MURPHY, Associated Press Health Writer Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients

Novo Undercuts Lilly’s Obesity Drug Price, Now Cheaper Than Car Payment  Just before the US cash session, Novo Nordisk A/S announced it will slash prices on

Robbie Williams warns GLP-1 drugs may cause vision loss. What does this mean for food & beverage innovation and natural alternatives?